A belief · not a fact · critically examined
WPATH SOC versions
WPATH's Standards of Care developed over four decades from a brief protocol (SOC1, 1979) into an extensive guideline (SOC8, 2022). According to the Cass Review, WPATH 8 overstates the strength of the evidence (source).
SOC1–SOC4 (1979–1990): the beginning
The first versions were drawn up by the Harry Benjamin International Gender Dysphoria Association (HBIGDA, named after Harry Benjamin), WPATH since 2007. They required a psychological assessment before hormones and a period of living in the desired role before surgery. See also the evidence-based objection.
SOC5–SOC7 (1998–2012): adolescents come into view
Around 2000 the SOC already described the possibility of puberty suppression in adolescents. SOC7 (2011/2012) no longer required living in the desired role as a condition for hormone treatment. For adolescents the SOC followed the Dutch Protocol, which rested on one cohort of 70 adolescents without a control group. See also Cass on puberty blockers.
SOC8 (2022): age limits and the Johns Hopkins reviews
Shortly after SOC8 was published, a correction of 15 September 2022 removed the proposed minimum ages for hormone treatment and surgery in adolescents; the correction gives no reason. According to The BMJ (31 October 2024), Johns Hopkins researchers who carried out systematic reviews for WPATH wrote that the client tried to restrict their ability to publish; WPATH denied having banned publication (source).
The WPATH Files published by Environmental Progress in 2024 contain messages from an internal WPATH forum; according to Environmental Progress they show that members know minors cannot oversee the lifelong consequences of treatment (source). That is the reading of Environmental Progress. See also the DSM evolution and the ICD evolution.
Assessment by external reviewers
The Cass Review (2024) had guidelines assessed with AGREE II: on rigour of development WPATH 2022 scored 35%, against 71% for the Swedish and 51% for the Finnish guideline (source). SBU Sweden (2022), NICE (2020) and COHERE Finland (2020) rated the evidence for hormonal treatment of young people as weak; the Norwegian board Ukom recommended in 2023 that these treatments be defined as experimental (source); see also the Norwegian guideline. In The BMJ, Jennifer Block (2023) described the growing professional disagreement (source). In the Netherlands, the Health Council judged on 30 June 2026 that care for young people is carefully organised, and rated the strength of the evidence as low to very low (source); see the Dutch rollout.
Frequently Asked Questions
According to the Cass Review, not in the sense of a rigorously developed guideline: WPATH 2022 scored 35% on rigour of development (AGREE II), and WPATH 8 overstates the strength of the evidence.
Leaked messages from an internal WPATH forum and a video of an internal panel discussion, published in March 2024 by Environmental Progress.
According to The BMJ (2024), Johns Hopkins researchers wrote that WPATH tried to restrict their ability to publish; WPATH denies having banned publication. It is a dispute, not established suppression.
Dutch care providers work with international guidelines, including WPATH. The Health Council judged in June 2026 that Dutch care is carefully organised, but rated the strength of the evidence as low to very low.
Sources
- Coleman E. et al. (2022). Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health.
- Environmental Progress / Hughes, M. (2024). The WPATH Files.
- Cass, H. (2024). Independent Review — Final Report. NHS England.
- SBU (2022). Hormonbehandling vid könsdysfori – barn och unga (SBU-rapport 342).
- Block, J. (2023). Gender dysphoria in young people is rising — and so is professional disagreement. BMJ. doi.org